|
|
|
26 Jun 2008 |
Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
|
|
26 Jun 2008 |
NeuroSearch successfully completes Phase I with ACR325 and announces the decision to progress development into Phase II Proof-of-Concept studies in Parkinson’s disease and Bipolar Disorder
|
|
26 Jun 2008 |
U.S. Food and Drug Administration Advisory Committee Recommends Approval of Tolvaptan, an Investigational Treatment for Hyponatremia
|
|
25 Jun 2008 |
Promising Results for Oral CP-4126
|
|
25 Jun 2008 |
SurModics Announces Initiation by Merck & Co., Inc. of Phase IIb Clinical Trial for I-vation(TM) TA
|
|
25 Jun 2008 |
Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
|
|
25 Jun 2008 |
Lux Biosciences Completes Enrollment in LUMINATE Pivotal Trial Program for Novel Uveitis Therapy, LUVENIQ(TM)
|
|
25 Jun 2008 |
Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients
|
|
25 Jun 2008 |
MethylGene Announces the Initiation of a Randomized, Three-Arm Phase II Trial of MGCD0103 in Combination With Vidaza® in Patients With High-Risk MDS or AML
|
|
24 Jun 2008 |
MediGene Achieves Positive Results with RhuDex(R) in Clinical Phase IIa Trial
|
|
24 Jun 2008 |
Novo Nordisk receives approval in the US for PrandiMet(TM)
|
|
24 Jun 2008 |
FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
|
|
24 Jun 2008 |
GPC Biotech Announces Initiation of NCI-Sponsored Phase 2 Trial of Satraplatin in Patients with Metastatic Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel
|
|
24 Jun 2008 |
Warner Chilcott Announces Approval of DORYX Delayed-Release 150 mg Tablets
|
|
24 Jun 2008 |
Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
|
|
24 Jun 2008 |
Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
|
|
23 Jun 2008 |
CB1400, patented by Canopus BioPharma, enters Phase II clinical trials for the prevention of mucositis in patients with cancer of the head and neck
|
|
23 Jun 2008 |
GSK update on FDA review of Promacta(R) (eltrombopag)
|
|
23 Jun 2008 |
A.P. Pharma Completes Enrollment in Phase 3 Trial of APF530
|
|
23 Jun 2008 |
Tranzyme Pharma Announces Successful Thorough QT/QTc Study of Ghrelin Agonist TZP-101
|
|
23 Jun 2008 |
Submit an sNDA for the immunosuppressant Prograf(R) for Ulcerative Colitis in Japan
|
|
22 Jun 2008 |
Welichem Completes Phase IIa Clinical Trial on Eczema
|
|
22 Jun 2008 |
YM Bioscience Annouces FDA Lifts Clinical Hold on Aerolef(R) and Clearance of a Phase II Clinical Trial
|
|
22 Jun 2008 |
Cytokinetics Announces Third Extension of Research Term Under Collaboration with GlaxoSmithKline
|
|
22 Jun 2008 |
NeuroSearch announces positive key results from a Phase II study with ABT-894 in adults with Attention Deficit-Hyperactivity Disorder (ADHD)
|
|
22 Jun 2008 |
FDA Approves GlaxoSmithKline's AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
|
|
22 Jun 2008 |
Merck Provides Update on U.S. Regulatory Status of MK-0524A (ER niacin/laropiprant) and MK-0524B (ER niacin/laropiprant/simvastatin)
|
|
22 Jun 2008 |
Aradigm Initiates Phase 2 Study of Inhaled Liposomal Ciprofloxacin in Bronchiectasis
|
|
19 Jun 2008 |
OSI Pharmaceuticals Initiates Clinical Development Program for Anti-Obesity Candidate, PSN602
|
|
19 Jun 2008 |
Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
|
|
19 Jun 2008 |
Axelar Initiates Phase I/II Clinical Trial on Cancer Patients with the New Anti-Cancer Drug AXL1717
|
|
19 Jun 2008 |
Sepracor Announces Phase III Data for Eslicarbazepine Acetate Presented at Ninth Eilat Conference on New Anti-Epileptic Drugs
|
|
19 Jun 2008 |
Suven Life Sciences Initiates Phase I Clinical Trials in Europe of SUVN-502 for Alzheimer’s disease
|
|
19 Jun 2008 |
Metabasis Announces Promising Results from Its Phase 1b Clinical Trial for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia
|
|
18 Jun 2008 |
Pfizer and Ranbaxy Settle Lipitor Patent Litigation Worldwide
|
|
18 Jun 2008 |
Theratechnologies Reports Positive 26-Week REsults Fro its Second Tesamorelin Phase 3 Trial
|
|
18 Jun 2008 |
Inotek Commences Phase 1 Trial in Glaucoma with Selective Adenosine 1 (A1) Agonist
|
|
18 Jun 2008 |
SkyePharma Announces Second Flutiform Phase III Efficacy Study Meets Primary Endpoints
|
|
18 Jun 2008 |
Acurox(TM) Tablets Meet Primary Endpoint In Pivotal Phase III Study
|
|
18 Jun 2008 |
Allergan Receives U.S. Food and Drug Administration Approval for TRIVARIS(TM) (triamcinolone acetonide injectable suspension) 80 mg/mL
|
|
18 Jun 2008 |
Algeta Begins Phase III Clinical Study of Alpharadin in Men with Advanced Prostate Cancer
|
|
18 Jun 2008 |
Elixir Pharmaceuticals Announces Ghrelin Agonist Data Presentation at the Endocrine Society Annual Meeting
|
|
17 Jun 2008 |
Genzyme Files Applications for Approval of Mozobil in the United States and Europe
|
|
17 Jun 2008 |
Rasilez(R) ASPIRE HIGHER clinical program expands to 35,000 patients in 14 trials, the largest cardio-renal outcomes program ever
|
|
17 Jun 2008 |
Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients with Ulcerative Colitis Published in Leading GI Journal
|
|
17 Jun 2008 |
Akesis Pharmaceuticals Reports Positive Results from its Phase IIa Trial of AKP-020 for Type 2 Diabetes
|
|
17 Jun 2008 |
Tranzyme Pharma's Ghrelin Agonist TZP-102 Demonstrates Safety and High Oral Bioavailability in the Successful Completion of a Phase I Trial
|
|
17 Jun 2008 |
Accentia Reports on Multiple Sclerosis Study: Revimmune(R) Shows Unprecedented Results in Reducing Disability and Improving Functions
|
|
17 Jun 2008 |
ARYx Therapeutics Inc. Commences Phase 2/3 Clinical Trial on Oral Anticoagulant Agent ATI-5923 - EmbraceAC Comparative Study Against Leading Anticoagulant Warfarin
|
|
17 Jun 2008 |
Hybrigenics receives authorization to accelerate inecalcitol dose escalation in Phase II trial for hormone-refractory prostate cancer
|
| |
|
Results 251 - 300 of 5216 |
